ICLR

Highlights Quarter one revenue of $2,034.0 million, an increase of 0.9% on quarter one 2025. Quarter one adjusted EBITDA of $317.7 million or 15.6% of revenue. GAAP net income for the quarter of $104.8 million or $1.36 diluted earnings per share. Quarter one   adjusted net income   of $192.9

DUBLIN --(BUSINESS WIRE)--Jun. 22, 2026-- ICON plc (NASDAQ: ICLR) today announced that it has selected Microsoft as a preferred technology partner – further advancing ICON’s previously announced plan to invest in digital innovation and AI over the next three years.

DUBLIN --(BUSINESS WIRE)--Jun. 17, 2026-- ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization, today announced that it will release its financial results for the first quarter 2026 after the market closes on Tuesday, June 23, 2026.

Highlights Quarter four revenue   was $2,112.5 million. Full year revenue was $8,251 million. Quarter four adjusted EBITDA of $327.1 million or 15.5% of revenue; full year adjusted EBITDA of $1,530.7 million or 18.6% of revenue. GAAP net income for the quarter of $149.2 million or $1.93 per diluted

DUBLIN --(BUSINESS WIRE)--May 26, 2026-- ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that it will release financial results for the fourth quarter and full year 2025 results after the market closes on Wednesday, May 27, 2026.

New, 69.5K square-foot, state-of-the-art clinic in Texas integrates clinical, laboratory, and pharmacy infrastructure all under one roof Two new satellite outpatient clinics in Texas and Kansas will further expand recruitment reach and reduce visit burden DUBLIN & SAN ANTONIO --(BUSINESS WIRE)--May

DUBLIN --(BUSINESS WIRE)--Apr. 29, 2026-- ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that the Audit Committee of the Board of Directors has completed its investigation into certain of the Company’s accounting practices and controls.

Partnership will integrate ICON’s clinical trial technology with Advarra’s purpose-built system for research sites, embedded across a broad, deeply established global network. Partnership will reduce administrative friction, accelerate study startup, and increase clinical trial participation.

Investigation’s preliminary indications are that 2023 and 2024 revenue may have been overstated by less than 2% for each fiscal year DUBLIN --(BUSINESS WIRE)--Feb. 12, 2026-- ICON plc, (NASDAQ: ICLR) today announced that it intends to release its fourth quarter and full year 2025 earnings results

DUBLIN --(BUSINESS WIRE)--Jan. 27, 2026-- ICON plc (NASDAQ: ICLR) today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois.

DUBLIN --(BUSINESS WIRE)--Dec. 9, 2025-- ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused

DUBLIN --(BUSINESS WIRE)--Dec. 2, 2025-- ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings underscore the need for a site-centric,

DUBLIN --(BUSINESS WIRE)--Nov. 12, 2025-- ICON plc , (NASDAQ: ICLR) a world-leading clinical research organisation, today announced that Mr. Barry Balfe , CEO of ICON plc and Mr. Nigel Clerkin , CFO of ICON plc , will present at the Jefferies London Healthcare Conference on Wednesday, November 19,